Current assessment of guidelines by a single-center approach to testicular tumor treatment

Abstract

Objectives: Testicular tumors make up approximately 1% of male malignant tumors. Because of the high rate of success in testicular tumors, mortality rates are very low. In our study, it is aimed to evaluatehistopathological results of the patients who had radical orchiectomy with prediagnosis of testicular tumor and treatments with oncologic outcomes for about 13 years. 

Material and Methods: Our study includes 138 patients with at least 12 months follow up on regular basis from 152 patients who had radical orchiectomy due to testicular mass between 2002 and 2015. The age of diagnosis of the patient, mass sizes, histopathological data, treatments, follow up and survival status were assessed retrospectively. 

Results: The average follow-up period was 80.7 months (16-166 months) in our study. In the analysis of 138 patients, it was seen seminomatous germ cell tumors (GCT) in 73 cases (52.9%), non- seminomatous GCT in 59 cases (42.7%) and sex cord stromal tumors in 3 cases (2.2%) and lymphoma in 3 cases (2.2%). During follow-up, recurrence was observed in 17 (13%) patients, disease-related death was occurred in 6 (4.7%) patients. Overall oncological success rate was 95.7%. 

Conclusion: Guide recommendations for treatment of testicular tumors are constantly updated. In our study, we also achieved an oncologic success consistent with the literature by updating treatment protocols according to changing guideline recommendations. 

Keywords

• Testis
• germ cell tumor
• nongerm cell tumor

Tek merkezin testis tümörü tedavisindeki yaklaşımı ile güncel kılavuzların değerlendirilmesi

Abstract

Amaç: Testis tümörleri erkeklerdeki malign tümörlerin yaklaşık %1’ini oluşturur. Testis tümörlerinde tedavi başarısının yüksek olması nedeniyle mortalite oranları oldukça düşüktür. Çalışmamızda son 13 yıl içinde kliniğimizde testis tümörü ön tanısıyla radikal orşiektomi yapılan hastaların histopatolojik değerlendirme sonuçları ile uygulanan tedavilerle beraber onkolojik sonuçların ortaya konulması hedeflenmiştir. 

Gereç ve Yöntemler: Bu çalışmaya 2002- 2015 yılları arasında kliniğimizde testiküler kitle sebebiyle radikal orşiektomi yapılmış 152 hastadan en az 12 aylık takibi olan ve takiplerine düzenli olarak gelen 138 hasta dahil edilmiştir. Hastaların tanı yaşı, kitle boyutları, histopatolojik verileri, uygulanan tedaviler, takip ve sağkalım durumu retrospektif olarak değerlendirildi. 

Bulgular: Çalışmamızdaki ortalama takip süresi 80,7 ay ( 16 ay - 166 ay ) idi. Malignite saptanan 138 hastanın 73’ ünde (% 52,9) seminomatöz Germ hücreli tümör (GHT), 59’ unda (%42,7) non-seminomatöz GHT ve 3’ ünde (%2,2) seks kord stromal tümör ve 3’ ünde (%2,2) lenfoma saptandı. Takip süresince 17 (%13) hastada nüks gelişirken, 6 hastada (%4,7) hastalığa bağlı ölüm gerçekleşti. Genel onkolojik başarı oranı % 95,7 olarak saptandı. 

Sonuç: Testis tümörü tedavisinde kılavuz önerileri sürekli güncellenmektedir. Biz de çalışmamızda değişen kılavuz önerilerine göre tedavi protokollerimizi güncelleyerek literatür ile uyumlu onkolojik başarı elde ettik. 

Keywords

• Testis
• germ hücreli tümör
• germ hücreli olmayan tümör

References

1. 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 6: 7-30.
2. 2. Albers P, Albrecht W, Algaba F, et al. Guidelines on Testicular Cancer: 2015 Update. Eur Urol 2015; 68: 1054-68.
3. 3. Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003; 170: 5-11.
4. 4. Mortensen MS, Lauritsen J, Kier MG, et al. Late relapses in stage I testicular cancer patients on surveillance. Eur Urol. 2016 Mar 17 [Epub ahead of print], doi: 10.1016/j.eururo. 2016.03.016.
5. 5. Hauptmann M, Fossa SD, Stovall M, et al. Increased stomach cancer risk following radiotherapy for testicular cancer. Br J Cancer 2015; 112: 44-51.
6. 6. Tandstad T, Ståhl O, Dahl O, et al. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy, a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol. 2016 Apr 6 [Epub ahead of print], pii: mdw164.
7. 7. Donohue JP, Thornhill JA, Foster RS, et al. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). J Urol 1995; 153: 85–9.
8. 8. Bokemeyer C, Kollmannsberger C, Stenning S, et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br J Cancer 2004; 91: 683–7.

9. 9. Fizazi K, Delva R, Caty A, et al. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study. Eur Urol 2014; 65: 381–6.
10. 10. Hanson HA, Anderson RE, Aston KI, et al. Subfertility increases risk of testicular cancer: evidence from populationbased semen samples. FertilSteril 2016; 105: 322-328.
11. 11. Ostrowski KA, Walsh TJ. Infertility with testicular cancer. UrolClin North Am 2015; 42: 409-20.
12. 12. Le Cornet C, Lortet-Tieulent J, Forman D, et al. Testicular cancer incidence to rise by 25% by 2025 in Europe? Modelbased predictions in 40 countries using population-based registry data. Eur J Cancer 2014; 50: 831-9.
13. 13. O’Shaughnessy MJ, Feldman DR, Carver BS, Sheinfeld J. Late relapse of testicular germ cell tumors. UrolClin North Am 2015; 42: 359-68.
14. 14. Nayan M, Jayalath VH, Jewett MA, Bedard PL, Hamilton RJ. Randomized controlled trials in testicular cancer: A demographic and quality assessment. UrolOncol 2016; 34: 7-13.
15. 15. Bosetti C, Bertuccio P, Chatenoud L, et al.Trends in mortality from urologic cancers in Europe, 1970-2008. Eur Urol 2011; 60: 1-15.